AIM ImmunoTech Inc.
AIM ImmunoTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88,000.00, down 48.2% from fiscal 2024. In the quarter to June 2026, revenue grew 4.00%, EPS grew 94.0% and free cash flow fell 167.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow AIM
AIM ImmunoTech Inc. (AIM) EV/Sales
As of 16 October 2026, AIM ImmunoTech Inc. (AIM) trades at a EV/Sales of −69.6×. Over the past ten years it has ranged from −158× (December 2022) to 464× (July 2021); the current reading is higher than 4% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −1.2× | — |
| FY2024 | 42.7× | (16.45%) |
| FY2023 | 51.1× | — |
| FY2022 | −130× | — |
| FY2021 | −42.1× | — |
| FY2020 | 113× | — |
| FY2019 | −1.7× | — |
| FY2018 | 22.8× | 5.66% |
| FY2017 | 21.6× | (77.57%) |
| FY2016 | 96.3× | 34.39% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −49.8× | — |
| Mar 2026 | −30.5× | — |
| Dec 2025 | −1.2× | — |
| Sep 2025 | 31.5× | (35.43%) |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AIM AIM ImmunoTech Inc. | −69.6× |
| SYBX Synlogic, Inc. compare | −0.2× |
| BCLI Brainstorm Cell Therapeutics Inc. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| NIKI Niki BioSolutions, Inc. compare | 1.3× |
| SKYE Skye Bioscience, Inc. compare | 12.9× |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | 24.2× |
| TCRT Alaunos Therapeutics, Inc. compare | 1,552× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)